CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 30, 2023--
Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the appointment of Christian Howell as Chief Commercial Officer (CCO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231030288290/en/
Christian Howell, Chief Commercial Officer, Cognito Therapeutics (Photo: Business Wire)
“Christian is an accomplished leader with a strong track record building commercial teams and driving global commercial launches in the medical device industry,” said Brent Vaughan, Chief Executive Officer at Cognito Therapeutics. “Over the last two decades, he has worked closely with public and private payers in the development of innovative reimbursement models, with key relationships with regulators, public and private payer organizations, top healthcare systems, and industry stakeholders. We look forward to Christian joining our executive leadership team, and his invaluable expertise and relationships will play a vital role in commercialization of our lead product in Alzheimer's and other neurodegenerative disorders.”
Christian brings more than 20 years of expertise in medical devices, where he navigated responsibilities in business development, commercial leadership, product management, market development, and strategy. Prior to joining Cognito, he was Senior Vice President and General Manager of Aetion’s Medical Device and Diagnostic Group. In this role, Howell was responsible for the commercialization of Aetion’s real-world evidence platform to the medical device and diagnostics industry. During his nearly 15 year tenure at Medtronic, Christian led Medtronic’s Value-Based Health Care Partnerships organization, as well as P&L responsibility for Medtronic’s Integrated Health Solutions program to improve delivery of care and patient experience with partner health systems.
Recognized as a forward-thinking industry leader in value-based healthcare, Howell has presented on payment system transformation and partnership strategies with healthcare professionals around the world. Howell is a former Officer in the United States Navy and holds a Bachelor of Science degree from Tulane University.
"I'm excited to be joining Cognito and for the opportunity to support its mission to advance disease-modifying therapies for patients with neurodegenerative diseases," said Christian Howell, Chief Commercial Officer for Cognito Therapeutics. “I am looking forward to working with the team to build upon our commercial strategy, with the ultimate goal of making a meaningful difference in the lives of patients with neurodegenerative diseases."
About Cognito Therapeutics
Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead therapy is currently in a pivotal study (HOPE) in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx.
View source version on businesswire.com:https://www.businesswire.com/news/home/20231030288290/en/
CONTACT: Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: TECHNOLOGY BIOTECHNOLOGY HEALTH NEUROLOGY CONSUMER PHARMACEUTICAL RESEARCH MEDICAL DEVICES SOFTWARE HARDWARE SCIENCE SENIORS DATA MANAGEMENT CLINICAL TRIALS
SOURCE: Cognito Therapeutics
Copyright Business Wire 2023.
PUB: 10/30/2023 08:00 AM/DISC: 10/30/2023 08:03 AM
http://www.businesswire.com/news/home/20231030288290/en
